Superior Planning, LLC’s Janux Therapeutics JANX Stock Holding History

Superior Planning, LLC’s Portfolio JANX Stock Details JANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$518	Buy	+30	New	+$504	﹤0.01%	1889

Other funds holding JANX

Federated Hermes Pittsburgh, Pennsylvania $71.4B AUM 33.43% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return

Nationale-Nederlanden Powszechne Towarzystwo Emerytalne Warszawa, Poland $2.08B AUM 157.4% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return

Panagora Asset Management Boston, Massachusetts $33.2B AUM 43.67% 1-Year Est. Return

Superior Planning, LLC's JANX Position: Q3 2026 in Review

Superior Planning, LLC opened a new position in Janux Therapeutics (JANX) in Q3 2026: 30 shares worth $518. The stake represents ﹤0.01% of the portfolio and ranks #1889 among its holdings.

106 funds tracked by Wall St. Rank hold JANX as of Q3 2026.

Superior Planning, LLC held 30 shares of Janux Therapeutics worth $518 as of Q3 2026.
Janux Therapeutics was a new Superior Planning, LLC position in Q3 2026.
Janux Therapeutics made up ﹤0.01% of Superior Planning, LLC's portfolio in Q3 2026, its #1889 holding.
106 funds tracked by Wall St. Rank held Janux Therapeutics as of Q3 2026.

Based on Superior Planning, LLC's 13F filing for Q3 2026, filed 12 Nov 2026.